Plant Summary
Plant Information
TCMBank_ID: | TCMBANKHE007245 |
ID: | TCMBANKHE007245 |
植物拉丁名: |
|
功能与主治: | To dispel wind and free network vessels, dissipate stasis and disperse swelling./Wind-damp impediment pain, knocks and falls. |
药用植物名: | 荷青花 |
药用部位: | root and rhizome |
TCM_ID_id: | 3276 |
植物对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN000047 | Chelerythrine | 34316-15-9 (Parent); CHEMBL1971693; 6471-86-9; Toddaline hydroxide; chelerythrine; [1,6-c]phenanthridinium, 1,2-dimethoxy-12-methyl-, hydroxide; SCHEMBL288916; UNII-65ML87R6OI; Chelerythrine aurichloride; AC1NS0S9; NSC76023; 1,2-dimethoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium hydroxide; Toddalin hydroxide; Chelerythrinium hydroxide; NSC-76023; Chelerythrine, compd. with gold chloride (AuCl3); (1,3)Benzodioxolo(5,6-c)phenanthridinium, 1,2-dimethoxy-12-methyl-, hydroxide (9CI); Chelerythrine hydroxide; Helleritrine hydroxide; NSC 76023; 65ML87R6OI; 478-03-5 | C21H19NO5 | 365.4 g/mol | C[N+]1=C2C(=C3C=CC(=C(C3=C1)OC)OC)C=CC4=CC5=C(C=C42)OCO5.[OH-] |
| TCMBANKIN009025 | cheliensisamine | AC1NSTHZ; 2-acetyl-2-amino-4-hydroxyindeno[1,2-b]oxet-3-one | C12H9NO4 | CC(=O)C1(C2=C(O1)C3=C(C2=O)C(=CC=C3)O)N | |
| TCMBANKIN019205 | Cryptogenin | Cryptogenine; 3-beta,26-Dihydroxycholest-5-ene-12,22-dione; cryptogenin; Cholest-5-ene-16,22-dione, 3beta,26-dihydroxy-, (20S,25R)- (8CI); Cryptogenine [French]; 3-beta,26-Dihydroxycholest-5-ene-12,22-dione [French]; BXC9X8B37J; 3beta,26-Dihydroxycholest-5-ene-16,22-dione; UNII-BXC9X8B37J; NSC 93751; Cholest-5-ene-16,22-dione, 3-beta,26-dihydroxy-, (20S,25R)- (8CI); Cholest-5-ene-16,22-dione, 3,26-dihydroxy-, (3-beta,25R)-; (3-beta,25R)-3,26-Dihydroxycholest-5-ene-16,22-dione | C27H42O4 | 430.62 | [H+].CC(CCC(=O)C(C)C1C(=O)CC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C)CO |
| TCMBANKIN020098 | chelirubine | C21H16NO5+ | 362.4 g/mol | C[N+]1=CC2=C3C(=CC(=C2C4=C1C5=CC6=C(C=C5C=C4)OCO6)OC)OCO3 | |
| TCMBANKIN026437 | chelilutine | AC1NSTI5; 1,2,5-trimethoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium | C22H20NO5+ | 378.4 g/mol | C[N+]1=C2C(=C3C(=CC(=C(C3=C1)OC)OC)OC)C=CC4=CC5=C(C=C42)OCO5 |
| TCMBANKIN026811 | chelidonine | CHEMBL1966935; Stylophorin; Prestwick0_000587; CHEBI:31389; AIDS002651; Prestwick2_000587; NSC646661 (FREE BASE); MEGxp0_001421; Chelidonine; AIDS-002651; BPBio1_000478; Prestwick1_000587; Prestwick3_000587; BSPBio_000434; 5b,6,7,12b,13,14-Hexahydro-13-methyl[1,3]benzodioxolo[5,6-c]-1,3-dioxolo[4,5-i]phenan-thridin-6-ol;[1,3]Benzodioxolo[5,6-c]-1,3-dioxolo[4,5-i]phenanthridin-6-ol, 5b,6,7,12b,13,14-hexahydro-13-methyl-, (5bR,6S,12bS)-; Chelidonin; NSC406034; SPBio_002653; 476-32-4; C12242; NSC-406034; ACon1_000007 | C20H19NO5 | 353.37 | CN1CC2=C(C=CC3=C2OCO3)C4C1C5=CC6=C(C=C5CC4O)OCO6 |
| TCMBANKIN031498 | chelerythrine methanolate | C22H21NO5 | 381.46 | CN1CC2=C(C=CC(=C2OC)OC)C3=C1C4=CC5=C(C=C4C(=C3)OC)OCO5 | |
| TCMBANKIN036851 | chenodeoxycholic acid | (3alpha,5beta,7alpha,8xi)-3,7-dihydroxycholan-24-oic acid; 3-alpha,7-alpha-Dihydroxycholanic acid; Anthropodesoxycholic acid; SMP1_000064; 7-alpha-Hydroxylithocholic acid; BSPBio_000190; Spectrum5_002009; JN3; CDCA; Acide chenodeoxycholique [INN-French]; Acidum chenodeoxycholicum [INN-Latin]; (4R)-4-[(3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid; 3-alpha,7-alpha-Dihydroxycholansaeure [German]; Cholan-24-oic acid, 3,7-dihydroxy-, (3-alpha,5-beta,7-alpha)- (9CI); (4R)-4-[(3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]valeric acid; Chenodesoxycholsaeure [German]; 5.BETA.-CHOLANIC ACID-3.ALPHA., SODIUM SALT; AIDS-045143; CCRIS 2195; Gallodesoxycholic acid; AIDS045143; Chenodiol (USAN); Chenix (TN); Chenix; 7alpha-hydroxylithocholic acid; SODIUM URSO; Prestwick1_000285; Chenic acid; 5-beta-Cholan-24-oic acid, 3-alpha,7-alpha-dihydroxy-; HSCI1_000210; D00163; chenodeoxycholicacid; Cholan-24-oic acid, 3,7-dihydroxy-, (3-.alpha., 5-.beta., 7-.alpha.)-; Chenodiol [USAN]; Anthropododesoxycholic acid; SPBio_002409; Prestwick0_000285; Anthropodeoxycholic acid; Cholan-24-oic acid, 3,7-dihydroxy-, (3alpha,5beta,7alpha)-; Chenodeoxycholic acid (JP15/INN); Chenodiol; NSC681066; CHEBI:16755; 474-25-9; Chenodeoxycholic acid; NSC-681066; 3-alpha,7-alpha-Dihydroxy-5-beta-cholan-24-oic acid; SBB002935; BPBio1_000210; 3alpha,7alpha-Dihydroxy-5beta-cholan-24-oic acid; Prestwick2_000285; Acido chenodeoxicholico [INN-Spanish]; LMST04010032; Chendol; C02528; EINECS 207-481-8; Prestwick3_000285; NSC 657949 | C24H40O4 | 392.57 | CC(CCC(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C |
| TCMBANKIN058003 | sanguinarine | Sanguinarine, 8CI); NSC-59270; sanguinarine ; NSC-35607; [1,6-c]-1,3-dioxolo[4,5-i]phenanthridinium, 13-methyl-, nitrate,sanguiritrin | C20H14NO4+ | 332.3 g/mol | C[N+]1=C2C(=C3C=CC4=C(C3=C1)OCO4)C=CC5=CC6=C(C=C52)OCO6 |
| TCMBANKIN058631 | stylopine | stylopine ; AKOS000277993; AC1LF4K6; SCHEMBL14703887; J0JS75Q12Z; BG01035160; l-Tetrahydrocoptisine; tetrahydrocoptisine; 2,3:9,10-Bis(methylenedioxy)-13a-alpha-berbine; l-Stylopine; MolPort-000-882-001; ZINC20470298; UNII-J0JS75Q12Z; AJ-77777; (1R)-5,7,17,19-TETRAOXA-13-AZAHEXACYCLO[11.11.0.0(2),(1)?.0?,?.0(1)?,(2)(3).0(1)?,(2)?]TETRACOSA-2,4(8),9,15(23),16(20),21-HEXAENE; (-)-Tetrahydrocoptisine; 4H-Bis(1,3)benzodioxolo(5,6-a:4',5'-g)quinolizine, 6,7,12b,13-tetrahydro-, (S)- (9CI); AKOS016023688; Stylopine; (S)-Stylopin; 13a-alpha-BERBINE, 2,3:9,10-BIS(METHYLENEDIOXY)- | C19H17NO4 | 323.34 | C1CN2CC3=C(CC2C4=CC5=C(C=C41)OCO5)C=CC6=C3OCO6 |
| TCMBANKIN059927 | Stypandrol | C26H22O6 | 430.4 g/mol | CC1=CC2=C(C(=C(C=C2)C3=C(C4=C(C=C3)C=C(C(=C4O)C(=O)C)C)O)O)C(=C1C(=O)C)O | |
| TCMBANKIN060947 | Sanleng acid | C18H34O5 | 330.46 | CCCCCCCCC(C(C=CC(CCCCC(=O)O)O)O)O | |
| TCMBANKIN061320 | cryptopine | C21H23NO5 | 369.41 | CN1CCC2=CC(=C(C=C2C(=O)CC3=C(C1)C4=C(C=C3)OCO4)OC)OC | |
| TCMBANKIN061353 | allocryptopine | CCG-104087;Oprea1_535693; .alpha.-Fagarine;alpha-allocryptopine;Fagarine I; beta-Allocryptopine; 3,4-Dimethoxy-6-methyl-5,7,8,15-tetrahydrobenzo[c][1,3]benzodioxolo[5,6-g]azecin-14(6H)-one; Allocrytopine; 5,7,8,15-Tetrahydro-3,4-dimethoxy-6-methylbenzo(e)(1,3)dioxolo(4,5-k)(3)benzazecin-14(6H)-one; AIDS-138447; .gamma.-Homochelidonine; 5,7,8,15-Tetrahydro-3,4-dimethoxy-6-methyl(1,3)benzodioxolo(5,6-e)(2)benzazecin-14(6H)-one; Thalictrimine; [1,3]Benzodioxolo[5,6-e][2]benzazecin-14(6H)-one, 5,7,8,15-tetrahydro-3,4-dimethoxy-6-methyl-; Allocryptopine; NSC148824; .beta.-Homochelidonine; ST5219181; ACon1_000293; BAS 00216246; Benzo(e)(1,3)dioxolo(4,5-k)(3)benzazecin-14(6H)-one, 5,7,8,15-tetrahydro-3,4-dimethoxy-6-methyl- (VAN) (8CI)(9CI); EINECS 207-626-5; Benzo(e)(1,3)dioxolo(4,5-k)(3)benzazecin-14(6H)-one, 5,7,8,15-tetrahydro-3,4-dimethoxy-6-methyl-; gamma-Homochelidonine; MLS000765018; Taliktrimin (thalictrimine); 24240-04-8; MEGxp0_001784; alpha-Allocryptopine; NSC 404531; NSC404531; NSC645286; Oprea1_700961; beta-Homochelidonine; .beta.-Allocryptopine; AIDS138447; .alpha.-Allocryptopine; alpha-Fagarine; CHEBI:17390; SMR000283023; Benzo[e][1,3]dioxolo[4,5-k][3]benzazecin-14(6H)-one, 5,7,8,15-tetrahydro-3,4-dimethoxy-6-methyl-; C02134; 485-91-6;beta-allocryptopine; 3,4-Dimethoxy-6-methyl-5,7,8,15-tetrahydrobenzo[c][1,3]benzodioxolo[5,6-g]azecin-14(6H)-one; AC1Q6OPD; 5,7,8,15-Tetrahydro-3,4-dimethoxy-6-methylbenzo(e)(1,3)dioxolo(4,5-k)(3)benzazecin-14(6H)-one; BDBM50130203; .gamma.-Homochelidonine; Taliktrimin; Bio-0227; STL372863; BG01657712; Taliktrimin (thalictrimine); MEGxp0_001784; 48216-02-0; HMS2735D09; BBL027872; FT-0632205; .beta.-Allocryptopine; MolPort-001-742-532; allo-cryptopine; alpha-Fagarine; SMR000283023; 3,4-dimethoxy-6-methyl-5,7,8,15-tetrahydro-[1,3]dioxolo[4',5':4,5]benzo[1,2-g]benzo[c]azecin-14(6H)-one; C02134; Benzo[e][1,5-k][3]benzazecin-14(6H)-one, 5,7,8,15-tetrahydro-3,4-dimethoxy-6-methyl- (VAN8C; [1,3]Benzodioxolo[5,6-e][2]benzazecin-14(6H)-one,5,7,8,15-tetrahydro-3,4-dimethoxy-6-methyl-; 5,7,8,15-Tetrahydro-3,4-dimethoxy-6-methyl(1,3)benzodioxolo(5,6-e)(2)benzazecin-14(6H)-one; Thalictrimine; Allocryptopin; MCULE-6414657551; 3,4-dimethoxy-6-methyl-5,6,7,8,14,15-hexahydrobenzo[c][1,3]dioxolo[4',5':4, 5]benzo[g]azecin-14-one; SCHEMBL673252; Q-100541; NSC-148824; Benzo(e)(1,3)dioxolo(4,5-k)(3)benzazecin-14(6H)-one, 5,7,8,15-tetrahydro-3,4-dimethoxy-6-methyl-; 24240-04-8; NSC404531; Fagarine I; CHEMBL520043; AKOS000730626; CHEBI:17390; AC1Q4720; beta-Allocryptopine; 7,8-dimethoxy-11-methyl-17,19-dioxa-11-azatetracyclo[12.7.0.0^{4,9}.0^{16,20}]henicosa-1(21),4(9),5,7,14,16(20)-hexaen-2-one; C-21100; AC1L409I; NSC-404531; NSC148824; BG00708515; BRD-K86670801-001-01-1; BAS 00216246; EINECS 207-626-5; 4CN-1540; alpha-Allocryptopine; W1169; EK27J8ROYB; beta-Homochelidonine; Oprea1_535693; 485-91-6; NSC645286; .alpha.-Fagarine; Allocrytopine; UNII-EK27J8ROYB; [1,3]Benzodioxolo[5,6-e][2]benzazecin-14(6H)-one, 5,7,8,15-tetrahydro-3,4-dimethoxy-6-methyl-; Allocryptopine; .beta.-Homochelidonine; 3,4-dimethoxy-6-methyl-5H,7H,8H,11H,15H-benzo[1'',2''-8',9']azecino[5',4'-2,1] benzo[4,5-d]1,3-dioxolan-14-one; ACon1_000293; NSC-645286; FT-0701356; HYBRYAPKQCZIAE-UHFFFAOYSA-N; Benzo(e)(1,3)dioxolo(4,5-k)(3)benzazecin-14(6H)-one, 5,7,8,15-tetrahydro-3,4-dimethoxy-6-methyl- (VAN) (8CI)(9CI); gamma-Homochelidonine; MLS000765018; NSC 404531; ST50219181; ZINC19204597; Oprea1_700961; 9084AF; .alpha.-Allocryptopine; 3,4-Dimethoxy-6-methyl-5,7,8,15-tetrahydrobenzo[c][1,3]benzodioxolo[5,6-g]azecin-14(6H)-one # | C21H23NO5 | 369.4 g/mol | CN1CCC2=CC3=C(C=C2C(=O)CC4=C(C1)C(=C(C=C4)OC)OC)OCO3 |
植物对应的疾病
| 疾病ID | 病名 | 疾病类型 | MeSH | 参考文献 |
|---|
植物对应的靶点
| 靶点ID | 基因名 | 基因别名 | 描述 | 染色体位置 | Map_Location | 基因类型 |
|---|
滇ICP备16009434号-1 |
Dai SX Lab